Alan M.

Schechter
3301 Marna Avenue, Long Beach, CA 90808-3251
949-701-5507 (M); 562-708-7796 (M); alanmschechter@gmail.com

SENIOR EXECUTIVE
Medical Device, Biotechnology, Healthcare
Raising Capital – Strategic Planning – Turn-Around Specialist – Strategic Alliances
New Business Development – Mergers and Acquisitions – Technology Licensing
Data Mining and Analytics – Medical Economics – Healthcare Informatics
Senior management executive with 30 years experience leading successful start-up
and turnaround companies. Identify strategic partners for licensing and acquisi
tion. Capitalize on technological innovations to position companies for growth a
nd acquisition. Strong general and P&L management. Bilingual: English and Spanis
h. Reading knowledge of French and Italian. Strong science background with MBA.
Strengths:
 Leadership/Restructuring – Turned around Laboratory Company, from net losses of $24
000,000 to $3,000,000 in net income in 10 months through overhauling operations.
Re-focused strategic direction of Genomics Company leading to strategic partner
ships with larger biotechnology companies.
 Team Building/Organizational Development – Re-energized company personnel during La
oratory turn-around and Genomics Company re-stratification.
 Entrepreneur/Technology Innovator – Founded six medical device and biotechnology co
panies. Holder of seven issued patents and fifteen patents pending in medical de
vices, biotechnology, and healthcare processes and algorithms.
 New Product Development – Invented, developed, and manufactured medical devices for
ophthalmic, spinal, orthopedic, cardiovascular, and minimally invasive surgery.
 Negotiator/Strategic Planning/Business Development – Raised over $30M in capital fo
start-up ventures, licensing technologies and sold companies exceeding $100M, a
nd performed M&A activities exceeding $250M. Wrote business plans for numerous
companies to coincide with funding.
 Medical Economics/Informatics Healthcare Analytics Expert – Developed innovative pr
cesses and algorithms in the analysis of medical economic and informatics health
care data.
 P&L Management – Responsible for multiple million dollar operations and research bu
gets.
 Areas of Expertise – Surgery: ophthalmic, cardiovascular, neuro, spinal, orthopedic
genomics, drug discovery, clinical laboratory, infectious disease, medical econ
omics, healthcare informatics

PROFESSIONAL EXPERIENCE
HERITAGE PROVIDER NETWORK, INC., Lancaster, CA, 2003–2008.
Privately held integrated delivery Managed Care Organization (staff model and IP
A groups) with over 500,000 members covering Southern California.
Director of Healthcare Informatics
Internal corporate consultant to company medical groups. Identified and provided
healthcare and medical information solutions. Converted raw data into usable i
nformation in order to make better financial, clinical, and operational decision
s.
 Developed a system to identify and stratify a population as a front end for popu
lation and disease management. This system has the potential to save millions o
f dollars by identifying at risk patients.
 Developed and implemented informatics metrics that saved the organization $2,500
,000/year by comparing group utilization and monitoring clinical decisions.
Alan M. Schechter Page 2
HERITAGE PROVIDER NETWORK, INC. – Director of Healthcare Informatics – continued
 Identified over-payments resulting in the recapture of over $3,000,000/year.
 Developed a process to identify errors or omissions in the Hierarchical Conditio
n Coding (“HCC†) for Medicare Advantage resulting in over a $15 million in increase in M
edicare reimbursement.
 Developed Health Risk Assessment algorithm to triage the health status of a pati
ent. This system has the potential to save millions of dollars by identifying a
t risk patients and patients whose treatment regiments need adjustment prior to
a catastrophic event.
 Invented and filed three patents for the identification and stratification of a
population; scoring system for determining the health risk of an individual; pro
cess and methodology for determining the qualitative relationships from the Qual
ity of Life metric scoring tool.
PYRO PHARMACEUTICALS, INC., Long Beach, CA, 1999–present
Biopharmaceutical research Company focused developing a new class of antibiotics
.
Chairman and Chief Executive Officer
 Founded Company based new class of antibiotics. Fourteen patents pending.
 Raised Series “A†round of financing $5,000,000. In progress of raising subseque
d.
 Developing new chemical entities based upon novel metabolic targets.

ALPHAGENE, INC., Woburn, MA, 1997–1998

Medical and functional genomics company focusing on the isolation and delivery o
f novel, full length disease and class related genes.
President and Chief Executive Officer
Recruited by Heidrick & Struggles. Full P&L responsibility. 5 direct, 45
indirect reports.
 Negotiated 3 exclusive multi-million dollar strategic alliances with biopharmace
utical companies.
 Reduced monthly burn-rate by more than $100,000 by restructuring and streamlinin
g internal operations, implementing SOP's, cross-training, and project protocols
.
 Refocused corporate strategic direction from a database supplier to a partner ce
ntric collaborator.
 Significantly improved company morale, motivation, cooperation, and communicatio
ns.
APPLIED CAROTENOID SCIENCES, INC., Long Beach, CA, 1994–1997
Bio-pharmaceutical device research and development company focusing on the thera
peutic treatment of cancer and cardiovascular disease. The Company licensed the
rights to its proprietary drug technology to a major pharmaceutical manufacturin
g company.
President and Chief Executive Officer
Full P&L responsibility for $10 million budget. 3 direct, 10 indirect rep
orts.
 Raised $10 million in seed capital from private investors.
 Developed strategic business plan for therapeutic applications of carotenoid tec
hnology.
 Licensed technology to a $9 billion pharmaceutical manufacturing company.
Alan M. Schechter Page 3
NOETIX MEDICAL TECHNOLOGIES, INC., Los Alamitos, CA, 1987–1994
$15 million per annum medical device manufacturing company specializing in minim
ally invasive tissue cutting systems for use in cardiovascular, orthopedic, opht
halmic, urological, gynecological and neurological surgery. The Company was acqu
ired by a $9 billion Japanese conglomerate.
Chairman and Chief Executive Officer
Full P&L responsibility for $10 million budget. 5 direct, 15 indirect rep
orts.
 Invented core technology (Six United States Patents issued).
 Raised in excess of $7.5 million in funding for the Company.
 Negotiated the marketing/distribution rights to a $4.5 billion company.
 Licensed technology to a $150 million and $9 billion company, respectively.
 Licensed technology to five other multi-million companies.
 Received eight 510K device approvals from the FDA.
 Established strategic plan for new product development and directed all aspects
of Company operation.
 Developed and implemented strategic business plan, managed marketing and sales,
financing, investor relations, legal and FDA interface.
VETERINARY REFERENCE LABORATORIES,, INC., Anaheim, CA, 1988–1990
VRL, a $30 million division of Animed, Inc., provided laboratory testing service
s to veterinarians. With 12 branch offices, VRL was the leading provider of vete
rinary laboratory services in the United States.
President and Chief Executive Officer
Turn-around company. Full P&L responsibility for $30 million budget. 15 di
rect, 1,500 indirect reports.
 Reorganized entire operation resulting in cost savings of $24 million, annualize
d.
 Implemented new operating policies that increased efficiency over 100%.
 Returned division to profitability/break-even in two months.
 Positioned company for successful acquisition to $2B Company for $175M.
 Significantly improved company morale, motivation, cooperation, and communicatio
ns

EDUCATION
MBA in Finance and Health Services Management, Golden Gate University, San Franc
isco, CA
MA in Molecular Biology, University of California, Berkeley, CA
MS in Biochemistry, New York University, New York, NY
BS in Biochemistry, SUNY @ Stony Brook, Stony Brook, NY

Alan M. Schechter Page 4

PATENTS
Capsulectomy Cutting Apparatus 4,911,161 March 27, 1990
Apparatus for Minimally Invasive Tissue Removal 5,403,276 April 4,
1995
Apparatus for Collecting and Staging Tissue 5,575,293 November 19,1996
Method and Apparatus for Minimally Invasive Tissue Removal 5,643,304
July 1, 1997
Method for Minimally Invasive Tissue Removal 5,669,876 September 23, 19
97
Method and Apparatus for Minimally Invasive Tissue Removal 5,685,840
November 11, 1997
Method for the identification and treatment of pathogenic microorganisms infecti
ons by inhibiting one or more enzymes in an essential metabolic pathway
6,955,890 October 18, 2005
Fifteen other patents pending
FORMER or CURRENT BOARD POSITIONS
HIMSS SoCal Chapter
HIMSS National Steering Committee on Patient Safety and Quality Outcomes
Success Profiles, Inc.
Wilshire Bioscience, Inc.
MediLite Diagnostica, Inc.
Tech Coast Advisory Group
Tech Coast Venture Network
California Venture Forum, Chairman
Orange County Biotechnology Alliance, Chairman
Ecumenical Council, Chairman
Southern California Biomedical Council
Communities in Schools, Orange County
CERTIFICATIONS
DataShaping Certified Professional 2008